generation run 2026-05-09
93 min completedmodel pipeline-v5plan not recordedrun/ad64543d…Selection
Verification
- record
- seen / partial
- working
The model's own caveats
- taper_protocol_no_rct
- taper_jurisdiction_limited
- no_1_4_bd_specific_protocol
Reproduce
- inputs
- 43 source keys (listed under Sources)
- plan
- not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
- model
- pipeline-v5
- streams
- none — agent transcripts are persisted from 2026-09 onward
20 searches — query, source, results, what was kept and why
| # | source | query | seen | kept | rationale |
|---|---|---|---|---|---|
| 1 | PubMed | 1,4-butanediol toxicity overdose case report | 1 | 1 | Key case report highlighting unique pharmacokinetic features of 1,4-BD overdose vs GHB |
| 2 | PubMed | 1,4-butanediol pharmacology GHB metabolism mechanism | 9 | 8 | All directly relevant to 1,4-BD pharmacology, mechanism of action, and metabolism |
| 3 | OpenAlex | 1,4-butanediol GHB precursor pharmacology | 10 | 6 | Most-cited landmark papers on GHB/1,4-BD pharmacology, toxicology, and transport |
| 4 | PubChem | 1,4-Butanediol | 1 | 1 | Primary chemical identity data — confirms molecular formula, weight, InChIKey |
| 5 | PubMed | GHB scheduling controlled substance regulation United States DEA | 1 | 1 | Relevant to regulatory context for GHB precursors |
| 6 | PubMed | 1,4-butanediol alcohol dehydrogenase conversion GHB metabolism ethanol interaction | 1 | 1 | Key metabolic pathway paper |
| 7 | PubMed | GHB receptor binding GABA-B agonist baclofen pharmacology CNS depressant | 8 | 6 | Direct receptor binding data and mechanism of action studies |
| 8 | PubMed · absence | GHB GABA-B receptor binding affinity Ki EC50 | 0 | 0 | Broadened to GABAergic mechanism search |
| 9 | PubMed | fomepizole treatment 1,4-butanediol GHB antidote alcohol dehydrogenase inhibitor | 2 | 2 | Key papers establishing antidote mechanism and ADH role |
| 10 | DEA PDF · absence | — | 0 | 0 | Attempted DEA document retrieval, unsuccessful |
| 11 | WebSearch | 1,4-butanediol SMILES CAS number industrial chemical | 10 | 0 | Chemical identity data and industrial context |
| 12 | WebSearch | 1,4-butanediol legal status scheduling UK US EU Australia controlled substance 2024 | 10 | 3 | Legal status across major jurisdictions - needed as fallback to structured APIs |
| 13 | WebSearch | 1,4-butanediol DEA controlled substance analog act United States scheduling history | 9 | 0 | US legal framework clarification |
| 14 | PubMed | GHB narcolepsy cataplexy sodium oxybate Xyrem FDA clinical use | 6 | 3 | History of GHB discovery (1960), schedule I/III legal framework, therapeutic uses |
| 15 | Crossref | DOI 10.2174/1570159x13666141210215423 | 1 | 1 | DOI verification for key GHB review paper |
| 16 | OpenAlex | GHB overdose management emergency supportive care | 6 | 3 | Overdose management and context for GHB as date-rape drug |
| 17 | WebFetch | — | 1 | 1 | EU-level regulatory context for 1,4-BD |
| 18 | OpenAlex | GHB tolerance dependence mechanism GABA receptor downregulation | 8 | 3 | Key papers on GHB/1,4-BD dependence mechanisms and interaction risks |
| 19 | WebSearch | 1,4-butanediol Canada CDSA schedule 2024 | 10 | 0 | Legal gap for Canada |
| 20 | WebSearch | GHB 1,4-butanediol Germany Netherlands EU legal status 2024 | 10 | 0 | EU legal landscape for 1,4-BD |
143 claims by section — every cited sentence, checked against its source
safety61 · 34 ok
An Australasian case series identified fatalities specifically linked to GHB and its precursorssupported
Study identifying deaths associated with GHB, GBL, and 1,4-BD overdose in Australasia pmid:15377240
GHB was identified in fatal drug poisoning cases across all five Nordic countries in 2012supported
GHB found in fatal poisoning cases across all five Nordic countries; polydrug use common j.forsciint.2015.01.003
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
1,4-Butanediol overdose produces toxicological features distinct from GHB intoxication: high anion gap metabolic acidosis (HAGMA) and elevated osmol gap resulting from 1,4-BD's own osmotic activity and its intermediary metabolitessupported
1,4-BD overdose caused high anion gap metabolic acidosis and osmol gap, mimicking toxic alcohol 15563650.2019.1617419
Claim in safety — not_supportednot supportedworking →
These findings mimic toxic alcohol poisoning (methanol, ethylene glycol), creating diagnostic confusion in emergency departments and potentially leading to inappropriate treatment. 1,4-BD is not detected by standard drug immunoassay screens; specific identification requires gas chromatography–mass spectrometry (GC-MS), though the osmol gap and HAGMA pattern can prompt clinical suspicion before laboratory confirmation.supported
1,4-BD overdose caused high anion gap metabolic acidosis and osmol gap, mimicking toxic alcohol 15563650.2019.1617419
Ethanol competitively inhibits ADH (Ki approximately 0.56 mM in human liver in vitro), blocking 1,4-BD → GHB conversion and causing 1,4-BD to accumulatesupported
ethanol competitively inhibits with Ki 0.56 mM; fomepizole most effective antidote s00210-011-0627-9
When ethanol is subsequently metabolized and cleared, rapid conversion of the accumulated 1,4-BD pool produces a delayed, potentially massive GHB surgesupported
ethanol blocks conversion of 1,4-BD to GHB while 1,4-BD potentiates some ethanol behavioral effects pmid:6717752
When ethanol is subsequently metabolized and cleared, rapid conversion of the accumulated 1,4-BD pool produces a delayed, potentially massive GHB surgesupported
ethanol interaction delayed GHB conversion; highest reported 1,4-BD blood concentration in literature 15563650.2019.1617419
Claim in safety — inconclusiveinconclusiveworking →
The majority of fatalities involve polysubstance use, particularly combinations with alcohol, opioids, or benzodiazepines.supported
polydrug use common j.forsciint.2015.01.003
High-dose GHB derived from 1,4-BD induced oxidative stress and lipid peroxidation in rat cerebral cortex at 120 mg/kgsupported
120 mg/kg 1,4-BD in rats increased chemiluminescence and TBA-RS, decreased TAR, indicating oxidative stress via lipid peroxidation pmid:19296210
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
GHB and by extension 1,4-BD as its prodrug have been documented as drug-facilitated sexual assault agents owing to rapid incapacitating effect, production of anterograde amnesia, near-tastelessness, and rapid urinary elimination (detection window under 12 hours).partially supported
Detection window: plasma 4-8h, urine 12h. Only 1.2% excreted unchanged pmid:15538955
GHB and by extension 1,4-BD as its prodrug have been documented as drug-facilitated sexual assault agents owing to rapid incapacitating effect, production of anterograde amnesia, near-tastelessness, and rapid urinary elimination (detection window under 12 hours).supported
Case report and review of GHB use for drug-facilitated sexual assault in Europe; 73 citations emj.2002.002402
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
GHB and its precursors, including 1,4-BD, are highly physically and psychologically addictivesupported
Concludes GHB and precursors are highly addictive via GABA-B mechanism pmid:24001290
The neurobiological basis of dependence involves chronic adaptations across GABA-B, GABA-A (β1-subunit), glutamate, dopamine, serotonin, norepinephrine, cholinergic systems, neurosteroidogenesis, and oxytocin pathways.partially supported
GABA-B bidirectional effects via GIRK channels, plus effects on dopamine, serotonin, NE, cholinergic systems, neurosteroidogenesis, oxytocin 000443173
Claim in safety — inconclusiveinconclusiveworking →
GHB/1,4-BD withdrawal is clinically comparable to alcohol and benzodiazepine withdrawal but progresses faster owing to GHB's short half-lifepartially supported
Rapid onset neuropsychiatric symptoms. No consensus on therapeutic management pmid:37560960
Rhabdomyolysissupported
Case series of severe GHB withdrawal including delirium, hemodynamic instability, and rhabdomyolysis ajad.70013
Duration is typically 5–7 days; one case documented recurrent withdrawal over 56 days.partially supported
Case of severe GHB withdrawal recurring over 56 days despite initial stabilization dar.13911
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Alternative and adjunctive agents include baclofen (GABA-B agonist), phenobarbital for benzodiazepine-resistant cases, pharmaceutical GHB (sodium oxybate) tapering as used in the Netherlands, and propofol in intensive care for the most severe presentationspartially supported
Animal studies support GABA-B agonist baclofen as more effective strategy for GHB withdrawal than benzodiazepines s12028-008-9062-2
Alternative and adjunctive agents include baclofen (GABA-B agonist), phenobarbital for benzodiazepine-resistant cases, pharmaceutical GHB (sodium oxybate) tapering as used in the Netherlands, and propofol in intensive care for the most severe presentationssupported
Case report: 11-day hospitalization for GHB withdrawal, resolved with baclofen as novel adjunct after usual supportive treatment cureus.25728
Alternative and adjunctive agents include baclofen (GABA-B agonist), phenobarbital for benzodiazepine-resistant cases, pharmaceutical GHB (sodium oxybate) tapering as used in the Netherlands, and propofol in intensive care for the most severe presentationssupported
Phenobarbital used for severe GHB withdrawal with benzodiazepine-resistant delirium/seizures dar.13556
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Ethanol both potentiates GHB's CNS depressant effects and competitively inhibits its formation from 1,4-BDsupported
ethanol blocks conversion of 1,4-BD to GHB while 1,4-BD potentiates some ethanol behavioral effects pmid:6717752
Ethanol both potentiates GHB's CNS depressant effects and competitively inhibits its formation from 1,4-BDpartially supported
ethanol competitively inhibits with Ki 0.56 mM s00210-011-0627-9
Ethanol both potentiates GHB's CNS depressant effects and competitively inhibits its formation from 1,4-BDpartially supported
ethanol interaction delayed GHB conversion 15563650.2019.1617419
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Multiple fatalities in the published literature involve GHB/1,4-BD combined with opioids.partially supported
polydrug use common j.forsciint.2015.01.003
Additive CNS and respiratory depression at intoxicating dosessupported
GHB causes collapse, convulsions, coma aggravated by alcohol and benzodiazepines cc6166
Additive CNS and respiratory depression at intoxicating dosessupported
respiratory depression and coma at high doses; cross-depressant with other CNS drugs jcph.1922
Barbiturates, sedative-hypnotics, antipsychotics, and ketamine all carry risk of additive CNS depression when combined with 1,4-BD.partially supported
GHB causes collapse, convulsions, coma aggravated by alcohol and benzodiazepines cc6166
In rats, diclofenac reduced brain GHB concentrations and attenuated respiratory depressionsupported
Diclofenac (NSAID) inhibits MCT1-mediated GHB transport into brain, reducing brain GHB concentration and respiratory depression in rats bdd.2296
In chemsex contexts, GHB/GBL/1,4-BD is frequently combined with antiretroviral medications containing CYP3A4/P-gp inhibitors (ritonavir, cobicistat)supported
Prevalence of chemsex including GHB/GBL in HIV clinic; concern about drug-drug interactions between chemsex drugs and ritonavir/cobicistat-containing antiretrovirals hiv.13239
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Concurrent opioid use: Additive respiratory depression; multiple documented fatalities.partially supported
GHB found in fatal poisoning cases across all five Nordic countries; polydrug use common j.forsciint.2015.01.003
Concurrent benzodiazepine or sedative-hypnotic use: Additive CNS depression at intoxicating doses.supported
GHB causes collapse, convulsions, coma aggravated by alcohol and benzodiazepines cc6166
Concurrent benzodiazepine or sedative-hypnotic use: Additive CNS depression at intoxicating doses.supported
cross-depressant with other CNS drugs; abuse/dependence/withdrawal risk jcph.1922
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
ADH1B variant carriers: Unpredictably slow 1,4-BD conversion creates risk of delayed, extended, or paradoxically intense intoxication.supported
ADH-IB G143A variant associated with slower metabolism pmid:17192771
NSAID use (particularly diclofenac): Potential alteration of GHB brain distribution via MCT1 inhibition; clinical significance unclear.supported
Diclofenac (NSAID) inhibits MCT1-mediated GHB transport into brain; NSAIDs may modulate GHB pharmacodynamics bdd.2296
Plasma GHB concentrations of approximately 100 mg/L produce euphoria and disinhibition, while concentrations approaching 500 mg/L have been associated with fatal cardiorespiratory depression — a five-fold range defining a dangerously narrow therapeutic-to-lethal window.supported
~100 mg/L plasma GHB causes euphoria/disinhibition; ~500 mg/L can cause death 1570159x13666141210215423
pharmacology20 · 16 ok
This conversion proceeds via a two-step oxidation catalyzed by alcohol dehydrogenase (ADH; 1,4-BD → 4-hydroxybutyraldehyde) and aldehyde dehydrogenase (ALDH; 4-hydroxybutyraldehyde → GHB)partially supported
1,4-BD conversion to GHB is catalyzed by ADH; ethanol competitively inhibits with Ki 0.56 mM s00210-011-0627-9
The ADH step is rate-limiting, confirmed in human liver cytosolic preparations and in living humans via the ADH inhibitor fomepizole.supported
1,4-BD conversion to GHB is catalyzed by ADH; fomepizole most effective antidote; confirms strong ADH involvement s00210-011-0627-9
The ADH step is rate-limiting, confirmed in human liver cytosolic preparations and in living humans via the ADH inhibitor fomepizole.supported
fomepizole (4MP) pretreatment significantly increased BDO plasma exposure, confirming ADH as primary 1,4-BD to GHB conversion pathway cpt.1306
The GABA-B receptor mediates the primary behavioral and pharmacological effects: GHB binds as a weak partial agonist (Ki ≈ 100 µM, EC50 ≈ 5 mM achieving approximately 69% of maximal baclofen response at recombinant GABA-B1/B2)partially supported
Ki values of GHB at GABA-B receptors ~100 microM across multiple radioligand assays pmid:9083788
The GABA-B receptor mediates the primary behavioral and pharmacological effects: GHB binds as a weak partial agonist (Ki ≈ 100 µM, EC50 ≈ 5 mM achieving approximately 69% of maximal baclofen response at recombinant GABA-B1/B2)supported
GHB activates GABA-B receptors with EC50 ~5 mM and maximal stimulation 69% vs L-baclofen (partial agonist) pmid:10587082
Genetic and pharmacological evidence identifies GABA-B as the essential mediator — GABA-B1 knockout mice lose all GHB pharmacological effects, and GABA-B antagonists (CGP 35348, SCH 50911) fully block sedation, ataxia, and discriminative stimulus effects.supported
GABA-B1 knockout mice lose all studied GHB behavioral effects despite retaining GHB-specific binding sites pmid:14656321
Genetic and pharmacological evidence identifies GABA-B as the essential mediator — GABA-B1 knockout mice lose all GHB pharmacological effects, and GABA-B antagonists (CGP 35348, SCH 50911) fully block sedation, ataxia, and discriminative stimulus effects.supported
GABA-B antagonists SCH 50911 and CGP 46381 completely prevented and reversed GHB sedation in mice pmid:11689189
Genetic and pharmacological evidence identifies GABA-B as the essential mediator — GABA-B1 knockout mice lose all GHB pharmacological effects, and GABA-B antagonists (CGP 35348, SCH 50911) fully block sedation, ataxia, and discriminative stimulus effects.supported
GABA-B antagonist CGP 35348 antagonized GHB and 1,4-BD effects pmid:12606639
Genetic and pharmacological evidence identifies GABA-B as the essential mediator — GABA-B1 knockout mice lose all GHB pharmacological effects, and GABA-B antagonists (CGP 35348, SCH 50911) fully block sedation, ataxia, and discriminative stimulus effects.supported
GHB and 1,4-BD occasioned >80% baclofen-lever responding, confirming GABA-B primary mechanism pmid:14742739
A distinct GHB-specific receptor — G-protein coupled, presynaptically localized — is supported by regional differences in cAMP inhibition (cortex and hippocampus but not thalamus or cerebellum), a pattern distinct from baclofen and blocked by the GHB-specific antagonist NCS-382 but not by GABA-B antagonistssupported
Evidence for a distinct GHB-specific G protein-coupled presynaptic receptor separate from GABA-B. GHB decreased adenylyl cyclase in cortex/hippocampus but not thalamus/cerebellum; different distribution from baclofen pmid:11032888
Claim in pharmacology — inconclusiveinconclusiveworking →
GHB also modulates dopamine release in the mesolimbic system (ventral tegmental area, nucleus accumbens), contributing to its euphoriant and reinforcing propertiessupported
effects on dopamine, serotonin, NE, cholinergic systems, neurosteroidogenesis, oxytocin 000443173
Chronic exposure additionally affects serotonergic, noradrenergic, and cholinergic neurotransmission, neurosteroidogenesis, and oxytocin release.supported
effects on dopamine, serotonin, NE, cholinergic systems, neurosteroidogenesis, oxytocin 000443173
Claim in pharmacology — inconclusiveinconclusiveworking →
The derived GHB metabolite peaked later (Tmax 39.4 ± 11.2 minutes, Cmax 45.6 ± 19.7 mg/L) with a half-life of 32.3 ± 6.6 minutes.supported
Max GHB concentration 45.6±19.7 mg/L at 39.4±11.2 min. GHB T1/2 32.3±6.6 min pmid:17192771
Compared to direct GHB administration, 1,4-BD produces a consistently longer duration of action attributable to the rate-limiting ADH conversion stepsupported
Showed 1,4-BD has similar onset but longer duration of action than GHB pmid:12606639
Claim in pharmacology — inconclusiveinconclusiveworking →
GHB crosses the blood-brain barrier via monocarboxylate transporters (MCT isoforms; Vmax approximately 709 nmol/min/g, Km approximately 11 mM) rather than passive diffusionsupported
GHB undergoes carrier-mediated transport (MCT isoform) across BBB with high-capacity, low-affinity kinetics pmid:15173314
Claim in pharmacology — inconclusiveinconclusiveworking →
A critical pharmacokinetic variable is ADH1B genotype: subjects carrying the ADH1B G143A variant showed a four-fold reduction in 1,4-BD oral clearance (CL/F 151.5 vs 598.8 mL/min·kg, p = 0.061), predicting marked inter-individual variability in GHB production rate and peak effect intensity from the same dose.partially supported
ADH-IB G143A variant associated with slower metabolism pmid:17192771
pharmacokinetic-detail12 · 11 ok
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
At 25 mg/kg (approximately 1.75 g for a 70 kg individual, equivalent to approximately 1.7 mL), subjects reported mild cognitive effects — reduced alertness, impaired concentration, and lightheadedness — along with transient blood pressure elevation and minor oxygen saturation decrease (mean SpO2 98.5% vs 99.6% placebo, p = 0.031)partially supported
Subjects felt less alert/awake in first 90 min pmid:17192771
Subjects carrying the ADH1B G143A variant allele demonstrated dramatically reduced 1,4-BD clearance: CL/F of 151.5 versus 598.8 mL/min·kg in wild-type subjects (p = 0.061)partially supported
ADH-IB G143A variant associated with slower metabolism pmid:17192771
Direct oral GHB pharmacokinetics (25 mg/kg, n = 8 healthy volunteers) show a Tmax of 20–45 minutes, elimination T1/2 of 30.4 ± 2.45 minutes, and volume of distribution of 52.7 ± 15.0 Lsupported
GHB plasma peak 39.4±25.2 mcg/mL at 20-45 min after 25 mg/kg oral GHB. T1/2 = 30.4±2.45 min, Vd 52.7±15.0 L pmid:15538955
Ethanol competitively inhibits ADH with a Ki of approximately 0.56 mM in human liver cytosolic preparationssupported
ethanol competitively inhibits with Ki 0.56 mM s00210-011-0627-9
When ethanol is subsequently cleared, rapid conversion of the accumulated 1,4-BD pool produces a delayed GHB surge, potentially overwhelming the individual with sudden, severe CNS depression.supported
ethanol blocks conversion of 1,4-BD to GHB while 1,4-BD potentiates some ethanol behavioral effects pmid:6717752
When ethanol is subsequently cleared, rapid conversion of the accumulated 1,4-BD pool produces a delayed GHB surge, potentially overwhelming the individual with sudden, severe CNS depression.supported
ethanol interaction delayed GHB conversion; highest reported 1,4-BD blood concentration in literature 15563650.2019.1617419
The MCT1 transporter is inhibited by diclofenac and potentially other NSAIDs, which reduced brain GHB concentrations and respiratory depression in animal models.supported
Diclofenac (NSAID) inhibits MCT1-mediated GHB transport into brain, reducing brain GHB concentration and respiratory depression in rats bdd.2296
No significant cytochrome P450 contribution has been identifiedsupported
confirming ADH as primary 1,4-BD to GHB conversion pathway cpt.1306
Approximately 500 mg/L plasma GHB: potentially fatal cardiorespiratory depressionsupported
~500 mg/L can cause death 1570159x13666141210215423
Approximately 100 mg/L plasma GHB: euphoria, disinhibitionsupported
~100 mg/L plasma GHB causes euphoria/disinhibition 1570159x13666141210215423
GBL converts to GHB with a half-life of approximately 1 minute — substantially faster than 1,4-BD's two-step ADH/ALDH pathwaypartially supported
GBL and 1,4-BD converted to GHB rapidly (t1/2 ~1 min) 1570159x13666141210215423
summary12 · 8 ok
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Once converted to GHB, 1,4-butanediol exerts effects primarily through weak partial agonism at GABA-B receptors (Ki ≈ 100 µM, EC50 ≈ 5 mM achieving approximately 69% of maximal baclofen response)partially supported
Ki values of GHB at GABA-B receptors ~100 microM across multiple radioligand assays pmid:9083788
Once converted to GHB, 1,4-butanediol exerts effects primarily through weak partial agonism at GABA-B receptors (Ki ≈ 100 µM, EC50 ≈ 5 mM achieving approximately 69% of maximal baclofen response)supported
GHB activates GABA-B receptors with EC50 ~5 mM and maximal stimulation 69% vs L-baclofen (partial agonist) pmid:10587082
GABA-B1 knockout mice lose all GHB pharmacological effects while retaining GHB-specific binding sites, and GABA-B antagonists fully block sedation and discriminative stimulus effectssupported
GABA-B1 knockout mice lose all studied GHB behavioral effects despite retaining GHB-specific binding sites pmid:14656321
GABA-B1 knockout mice lose all GHB pharmacological effects while retaining GHB-specific binding sites, and GABA-B antagonists fully block sedation and discriminative stimulus effectspartially supported
GABA-B antagonist CGP 35348 antagonized GHB and 1,4-BD effects pmid:12606639
A distinct high-affinity GHB receptor (Kd ≈ 95 nM) may mediate prosocial and euphoric effects not shared by baclofen.partially supported
two GHB binding site affinities (Kd 95 nM and 16 microM) pmid:1487112
ADH1B genotype variants produce up to four-fold differences in conversion rate, and ethanol co-ingestion competitively inhibits ADH, causing delayed but potentially lethal GHB surges when ethanol clearspartially supported
ADH-IB G143A variant associated with slower metabolism pmid:17192771
ADH1B genotype variants produce up to four-fold differences in conversion rate, and ethanol co-ingestion competitively inhibits ADH, causing delayed but potentially lethal GHB surges when ethanol clearspartially supported
ethanol interaction delayed GHB conversion; highest reported 1,4-BD blood concentration in literature 15563650.2019.1617419
Claim in summary — inconclusiveinconclusiveworking →
Plasma GHB concentrations of approximately 100 mg/L produce euphoria while approximately 500 mg/L approach fatal cardiorespiratory depression, leaving minimal margin between desired effects and overdose.supported
~100 mg/L plasma GHB causes euphoria/disinhibition; ~500 mg/L can cause death 1570159x13666141210215423
neuroscience10 · 6 ok
In rat cerebral cortex, high-dose GHB derived from 1,4-BD administration (120 mg/kg) induced oxidative stress and lipid peroxidationsupported
120 mg/kg 1,4-BD in rats increased chemiluminescence and TBA-RS, decreased TAR, indicating oxidative stress via lipid peroxidation pmid:19296210
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Pharmacogenomic risk stratification: ADH1B genotype produces four-fold pharmacokinetic variability, but no study has correlated genotype with clinical outcomes such as overdose, dependence severity, or withdrawal trajectory.partially supported
ADH-IB G143A variant associated with slower metabolism pmid:17192771
Claim in neuroscience — inconclusiveinconclusiveworking →
This produces the sedative, muscle-relaxant, and anxiolytic effects that dominate the subjective experiencepartially supported
GABA-B antagonists SCH 50911 and CGP 46381 completely prevented and reversed GHB sedation in mice pmid:11689189
Claim in neuroscience — not_supportednot supportedworking →
Brain Fos expression mapping reveals that GHB activates neural populations in the median raphe nucleus and lateral habenula — regions involved in serotonergic mood regulation and aversive/reward processing, respectively — that baclofen does not activatesupported
GHB activates distinct brain regions vs baclofen; unique activation of raphe nucleus and lateral habenula j.neuroscience.2008.10.011
Chronic GHB/1,4-BD use has been associated with cognitive impairment in a systematic review of clinical and recreational users, including deficits in working memory and attention.supported
Systematic review of cognitive impairments associated with GHB use, both clinical and recreational 1570159x19666210610094352
Functional significance of the GHB-specific receptor: High-affinity GHB binding sites (Kd ≈ 95 nM) persist in GABA-B1 knockout mice, but no knockout or selective antagonist studies have determined whether GHB-specific receptor activation is necessary or sufficient for euphoria, prosocial effects, or therapeutic benefit in narcolepsy.supported
GABA-B1 knockout mice lose all studied GHB behavioral effects despite retaining GHB-specific binding sites pmid:14656321
history9 · 6 ok
Claim in history — not_supportednot supportedworking →
Treatment admissions for GHB-related dependence have increased sharply in the Netherlands and other European countries, and fatalities involving GHB and its precursors have been documented across Australasia and the Nordic countries.partially supported
Study identifying deaths associated with GHB, GBL, and 1,4-BD overdose in Australasia pmid:15377240
Treatment admissions for GHB-related dependence have increased sharply in the Netherlands and other European countries, and fatalities involving GHB and its precursors have been documented across Australasia and the Nordic countries.partially supported
GHB found in fatal poisoning cases across all five Nordic countries; polydrug use common j.forsciint.2015.01.003
Gamma-hydroxybutyric acid (GHB), the active metabolite of 1,4-butanediol, was first synthesized by Henri Laborit in 1960 at the Institut Biomédical des Cordeliers in Paris as part of a program to develop GABA analogs capable of crossing the blood-brain barrierpartially supported
Historical overview: GHB discovered in 1960 pmid:15061684
Claim in history — not_supportednot supportedworking →
GHB and its precursors, including 1,4-BD and gamma-butyrolactone (GBL), were sold without restriction through supplement channelssupported
1980s bodybuilding/weight loss use pmid:15061684
Concurrent reports of GHB's use as a drug-facilitated sexual assault agent attracted law enforcement and legislative attention.supported
Case report and review of GHB use for drug-facilitated sexual assault in Europe; 73 citations emj.2002.002402
FDA approval of sodium oxybate for narcolepsy with cataplexy followed in July 2002.supported
FDA approved sodium oxybate 2002 for narcolepsy/cataplexy pmid:15061684
Claim in history — inconclusiveinconclusiveworking →
receptor-pharmacology8 · 8 ok
Binding characterization established a Ki ≈ 100 µM for displacement of radiolabeled baclofen at GABA-B sitessupported
Ki values of GHB at GABA-B receptors ~100 microM across multiple radioligand assays pmid:9083788
Functional assays at recombinant GABA-B1/B2 receptors expressed in Xenopus oocytes demonstrated an EC50 ≈ 5 mM, with maximal efficacy reaching approximately 69% of the full agonist baclofen responsesupported
GHB activates GABA-B receptors with EC50 ~5 mM and maximal stimulation 69% vs L-baclofen (partial agonist) pmid:10587082
The GABA-B antagonists CGP 35348, SCH 50911, and CGP 46381 completely antagonize GHB-induced sedation and ataxia.partially supported
GABA-B antagonists SCH 50911 and CGP 46381 completely prevented and reversed GHB sedation in mice pmid:11689189
In rats trained to discriminate baclofen, both GHB and 1,4-BD occasion greater than 80% baclofen-lever responding, confirming GABA-B as the shared discriminative mechanism.supported
GHB and 1,4-BD occasioned >80% baclofen-lever responding, confirming GABA-B primary mechanism pmid:14742739
Two binding populations have been characterized: a high-affinity site (Kd ≈ 95 nM) and a low-affinity site (Kd ≈ 16 µM).supported
two GHB binding site affinities (Kd 95 nM and 16 microM) pmid:1487112
This effect is blocked by the GHB-specific antagonist NCS-382 but not by GABA-B antagonists, confirming receptor independence.partially supported
Evidence for a distinct GHB-specific G protein-coupled presynaptic receptor separate from GABA-B pmid:11032888
These GHB-specific activations may underlie the prosocial effects, euphoria, and subjective qualities that differentiate GHB from pure GABA-B agonists such as baclofen.supported
GHB has prosocial, euphoric effects not shared by baclofen, suggesting other receptor mechanisms j.neuroscience.2008.10.011
GHB modulates dopamine release in the mesolimbic pathway (ventral tegmental area → nucleus accumbens) through both GABA-B–mediated disinhibition and possibly direct GHB receptor mechanismssupported
GABA-B bidirectional effects via GIRK channels, plus effects on dopamine 000443173
comparative-pharmacology7 · 5 ok
Baclofen has been used therapeutically to manage GHB/1,4-BD withdrawal, leveraging GABA-B agonism to substitute for the missing GHB stimulus.partially supported
Animal studies support GABA-B agonist baclofen as more effective strategy for GHB withdrawal than benzodiazepines s12028-008-9062-2
Baclofen has been used therapeutically to manage GHB/1,4-BD withdrawal, leveraging GABA-B agonism to substitute for the missing GHB stimulus.supported
Case report: 11-day hospitalization for GHB withdrawal, resolved with baclofen as novel adjunct after usual supportive treatment cureus.25728
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
In discriminative stimulus studies in rats, both GHB and 1,4-BD fully substitute for baclofen, confirming identical receptor mechanismssupported
GHB and 1,4-BD occasioned >80% baclofen-lever responding, confirming GABA-B primary mechanism pmid:14742739
The key pharmacological distinction is that 1,4-BD produces a consistently longer duration of action than equi-effective GHB doses, attributable to the rate-limiting ADH conversion step.supported
Showed 1,4-BD has similar onset but longer duration of action than GHB pmid:12606639
Brain Fos mapping demonstrates that GHB uniquely activates the median raphe nucleus and lateral habenula, regions not activated by baclofen.supported
unique activation of raphe nucleus and lateral habenula. GHB has prosocial, euphoric effects not shared by baclofen j.neuroscience.2008.10.011
clinical-evidence3 · 2 ok
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Evidence-based consensus guidelines for GHB dependence management have been published, though these address the dependence that GHB/1,4-BD use produces rather than therapeutic use of 1,4-BD itself.supported
BAP guidelines covering pharmacological management of GHB dependence among other substances 02698811251399593
Liakoni and colleagues demonstrated that fomepizole (4-methylpyrazole), an ADH inhibitor, markedly reduces 1,4-BD → GHB conversion in humans, establishing proof of concept for a pharmacological intervention in 1,4-BD intoxication.supported
fomepizole (4MP) pretreatment significantly increased BDO plasma exposure, confirming ADH as primary 1,4-BD to GHB conversion pathway cpt.1306
chemistry1 · 0 ok
Claim in chemistry — inconclusiveinconclusiveworking →